Axiogenesis is the world leader in developing and producing stem cell-derived cardiomyocytes, both human and murine (mouse), as well as other cell types. Through genetic modification and selection, Axiogenesis has patented a process for the cell-type specific selection of (heart) cells, allowing for the production of cell cultures that are virtually 100% pure and genetically homogeneous.
Axiogenesis produces induced pluripotent stem (iPS) cell-derived cell types, both human and murine, in addition to murine embryonic stem cell (ESC) derived cells. Mouse iPSC heart muscle cells (Murine cardiomyocytes) were launched in 2008 (Cor.At®) and human iPSC cardiomyocytes (Cor.4U®) were launched in 2012.
Axiogenesis is the market leader in ready-to-use murine stem cell-derived cardiomyocytes and has also produced several other tissue-specific cells using murine embryonic stem cells as the source (skin, endothelial, neuronal, liver etc.).